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FibrosisCertain macrophage phenotypes contribute to tissue ﬁbrosis, but why? Tissues host resident mononuclear
phagocytes for their support to maintain homeostasis. Upon injury the changing tissue microenvironment
alters their phenotype and primes inﬁltrating monocytes toward pro-inﬂammatory macrophages. Several
mechanisms contribute to their deactivation and macrophage priming toward anti-inﬂammatory and
pro-regenerative macrophages that produce multiple cytokines that display immunosuppressive as well as
pro-regeneratory effects, such as IL-10 and TGF-beta1. Insufﬁcient parenchymal repair creates a tissue micro-
environment that becomes dominated by multiple growth factors that promote the pro-ﬁbrotic macrophage
phenotype that itself produces large amounts of such growth factors that further support ﬁbrogenesis.
However, the contribution of resident mononuclear phagocytes to physiological extracellular matrix turnover
implies also their ﬁbrolytic effects in the late stage of tissue scaring. Fibrolytic macrophages break down ﬁbrous
tissue, but their phenotypic characteristics remain to be described in more detail. Together, macrophages
contribute to tissue ﬁbrosis because the changing tissue environments prime them to assist and orchestrate
all phases of tissue injury and repair. This article is part of a Special Issue entitled: Fibrosis: Translation of basic
research to human disease.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Fibrogenesis has been maintained throughout evolution because
of its live-saving beneﬁts during the wound healing processes that
occur after injury. On the other hand ﬁbrogenesis contributes to many
chronic progressive disease states.
In general, any kind of injury involves a sequence of responses to
control the injurious trigger that restore homeostasis [1]. Tissue
loss, either by trauma or by the collateral damage during the inﬂam-
matory phase, requires tissue repair, which involves scaring. Cells of
the monocyte/macrophage lineage are central players of the immune
response following tissue damage.Macrophages havemany functions,
including the promotion and resolution of inﬂammation, the removal
of apoptotic cells, and the support of cell proliferation following injury.
Macrophages exist in several different phenotypic states within the
injured tissue and promote inﬂammation and at the same time are
beneﬁcial for the repair of healing tissue.s: Translation of basic research
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rights reserved.In this review, we will summarize how mononuclear phagocytes,
especially macrophages, are involved in the various stages of tissue
injury and repair. The different and speciﬁc roles of macrophages
during parenchymal repair, mesenchymal repair, and ﬁbrolysis become
more obvious from the perspective of the tissues' needs to regain ho-
meostasis upon injury.
2. Phases of tissue injury and repair
2.1. The injury phase
Pathogen entry, toxic or oxidative stress often causes necrotic cell
death, which implies the release of damage- and pathogen-associated
molecular patterns (DAMPs or PAMPs) released by necrotic cells and/
or microorganisms, respectively. These have an identical capacity to
activate toll-like receptors (TLRs), NOD-like receptors (NLRs), C-type
lectin receptors (CLRs) or inﬂammasomes for the secretion of cytokines
and chemokines, which set up tissue inﬂammation and leukocyte
recruitment [2–6]. The associated immunopathology often largely con-
tributes to acute impairment of tissue dysfunction or mortality, e.g. in
sepsis, pneumonia,meningitis, or acute kidney injury. The antimicrobial
activity of recruited immune cells involves reactive oxygen species pro-
duction, enzyme and pro-inﬂammatory cytokine release. Furthermore,
a persistent accumulation of immune cells may prolong tissue inﬂam-
mation and aggravate immunopathology.
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Mechanisms that control inﬂammatory processes and restore
homeostasis are crucial for efﬁcient recovery and preserving tissue
morphology and function [7]. Inﬂammation suppresses tissue repair,
which implies that the resolution of inﬂammation is necessary to
tip the balance to parenchymal repair and healing. One of the events
participating in these changes is the decreasing amount of DAMPs and
PAMPs and the high number of apoptotic neutrophils that need to be re-
moved by macrophages. This process not only turns pro-inﬂammatory
into anti-inﬂammatory macrophages that secrete large amounts of
IL-10 and TGF-β [8,9], but the sequential activation of transcription fac-
tors either also promotes inﬂammation such as NF-κB [10] and IRF-1
[11] and subsequently its resolution like IRF-4 [12,13].
2.3. The epithelial and vascular repair phase
Restoring tissue integrity after any kind of injury may be achieved
by proliferation of 1. surviving cells, 2. local progenitor cells, and 3.
bone marrow-derived precursors [14,15]. The capacity for tissue re-
generation varies between different organs. While blood cells easily
and completely regenerate from hematopoietic stem cells inside the
bone marrow the capacity of vascular regeneration, again from endo-
thelial progenitors inside the bone marrow, is already somewhat
limited, especially in chronic disease states, like uremia [16–18].
Remote cellular compartments in solid organs may not even be acces-
sible to bone marrow-derived stem cells even though these still pro-
mote repair by paracrine secretion of growth factors [19]. Therefore,
especially epithelial structures, like the epidermis, the intestinal
epithelium and renal podocytes or tubular epithelial cells rely on local
committed progenitor cells for repair [15,20].
2.4. Mesenchymal repair
Fibrotic tissue seals and mechanically stabilizes the “wound” only
when damage is not limited to the epithelium and/or repair is not
fast enough [21]. This may involve partial loss of organ function also
because ﬁbrosis involves sclerosis that e.g. functionally restricts the
ﬂexibility of skin/joints/small bowel; affects electric circuits and he-
modynamics in the heart; reduces arteriolar compliance followed by
arterial hypertension or causes persistent proteinuria from the renal
glomeruli. Cellular and molecular events in mesenchymal healing
(ﬁbrosis) include 1. inﬁltration of immune cells and ﬁbrocytes, 2. ac-
cumulation of extracellular matrix (ECM), 3. activation of ﬁbroblasts
andmyoﬁbroblasts, and 4. angiogenesis [22]. Fibrosis is often associated
with persistent inﬂammation and loss of organ function, i.e. chronic
disease [23]. Their causal relationship is often anticipated but remains
unclear [24].
2.5. Minimizing scars
Extracellular matrix (ECM) turnover during homeostasis already
implies that interstitial cells release proteases and that phagocytes re-
move ECM breakdown products [25]. Scars shrink by reducing excess
ECM via enzymatic activity, e.g. by matrix metalloproteases (MMP).
Factors that limit ﬁbrogenesis and promote ﬁbrolysis are prostaglandin
E2 [26] or caveolin-1 and BMP7 [27,28]. Furthermore, recombinant
TGF-β3 application in humans' skin injury supports ECM breakdown
and scarless healing [29]. TGF-β3 application prevents excessive prolif-
eration of myoﬁbroblasts and changes their migration toward a pattern
normally seen only in the fetal stage where scarless healing occurs [29].
3. Origin and diversity of monocytic phagocytes in healthy tissues
Macrophage development is controlled by CSF-1R, also known as
macrophage colony-stimulating factor-1 receptor, which is expressedon all monocyte progenitors [30]. Ligation of this receptor activates
the myeloid developmental regulator PU.1. Mice deﬁcient in CSF-1R
or its ligand do not develop any monocyte, macrophages or dendritic
cells [31]. Other essential factors responsible for the development of
myeloid cells include IRF8, KLF4, c-Maf and many more molecules,
which function have not been precisely described yet [30]. The
phenotype of circulating monocytes signiﬁcantly differs in terms of
their response to infection and inﬂammation [32]. Monocytes circu-
late in blood and migrate into tissues where they mature and develop
into macrophages. Human monocytes consist of three subsets which
appear to be responsible for different processes. The new classiﬁcation
ofmonocytes is based on the expression of CD14/CD16 and Ly6C/CD43
in human and mice respectively [32]. CD14++CD16− (in mice
Ly6C++CD43+) monocytes are commonly referred to as the ‘classi-
cal monocytes’ which produce high levels of TNF-α and MHC II [33]
and are the major population of human monocytes. They also express
CCR2 and, therefore, respond to CCL2 for transendothelial migration
and secretion of additional pro-inﬂammatory cytokines [34,35].
Most of these circulating monocytes become pro-inﬂammatory
tissue macrophages once they exit the vasculature. By contrast
‘nonclassical’ CD14+CD16++ monocytes (in mice Ly6C+CD43++)
and ‘intermediate’ monocytes (CD14++CD16+ subsets in humans
and Ly6C++CD43− in mice) are in the minor population. The ‘inter-
mediate’ subset expresses surfacemarkers at levels between ‘classical’
and ‘nonclassical’ subsets [36–38]. ‘Nonclassical’ monocytes were
shown to response poorly to LPS but still are able to produce TNF-α.
By contrast CD14++CD16+ ‘intermediate’ monocytes show high
expression of TLR4, increased phagocytic activity and decreased
antigen presentation. By contrast LPS-stimulated CD14++CD16+
monocytes produced more IL-10 than ‘nonclassical’ monocytes and
showed anti-inﬂammatory functions [39]. This heterogeneity of
mononuclear phagocytes in healthy or injured tissues relates to differ-
ent microenvironments in different tissue compartments that also
undergo changes during the different phases of dynamic disease
processes, which then is associatedwith shifts toward differentmono-
cytic phagocyte populations. This phenotype plasticity is the reason
whymost of the in vivo studies failed to reveal pure macrophage clus-
ters of a single phenotype [40–42]. A detailed discussion of classifying
macrophages by their surface marker expression proﬁles has been
provided elsewhere [41–44]. In vivo, macrophages are present in
all tissues and participate in maintaining homeostasis. For example,
the lung and liver are exposed to pathogens from the air or pathogen
components from the intestines, respectively, which explain the pre-
dominance of macrophages that can clear pathogen components by
phagocytosis. Also the bone marrow requires macrophages for the
clearance of the nuclei expelled from erythroblasts [45]. The intestinal
mucosa rather hosts dendritic cells that pick up signals from the
microbiota to secrete mitogenic mediators that support the mainte-
nance of the intact epithelial lining [46]. Sterile organs rather harbor
dendritic cells that process autoantigens and send tolerogenic signals
to lymphocytes in regional lymphnodes as a mechanism of peripheral
tolerance [47,48].
Together, already during homeostasis different organs provide
unique microenvironments, which generate different shapes and
functional properties of their resident mononuclear phagocytes,
e.g. resident dendritic cells or rather resident tissue macrophages. Tis-
sue injuries suddenly change the organ-speciﬁc environment, which,
depending of the type of injury, leads to adaptive changes of the resi-
dent mononuclear phagocytes as well as of the inﬁltrating monocytes.
4. Monocytic phagocytes in the tissue injury/inﬂammation phase
PAMPs and DAMPs are responsible for generating pro-inﬂammatory
macrophage subsets during infections and sterile tissue injury, respec-
tively, because they activate pattern-recognition receptors on the mac-
rophage surface [4–6]. These macrophages secrete pro-inﬂammatory
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neutrophils or natural killer cells [49,50]. Furthermore, such activated
macrophages have the ability to kill intracellular bacteria and have a
phenotype proposed by in vitro studies as M1 macrophages (Fig. 1,
Table 1). M1amacrophages were deﬁned by IFN-γ and LPS stimulation,
whereas M1b macrophages by stimulation with PAMPs. Generally, in-
ﬂammatoryM1amacrophages secrete IL-1, IL-12, IL-23, tumor necrosis
factor (TNF)-α and reactive oxygen species. They express high levels of
inducible nitric oxide synthase, major histocompatibility complex class
II (MHCIIhigh) and IL-1R [42]. They have enhanced phago- and endocytic
abilities and increased expression of co-receptors required for antigen
presentation but cannot efﬁciently ingest apoptotic cells. This bacteri-
cidalmacrophage phenotype appears in the early phases of tissue injury
shortly to enforce local host defense against pathogens, a process that is
potentially life-saving during infections but also causes collateral tissue
damage [42,51,52]. However, sterile injuries induce inﬂammation
similar to injury caused by pathogens [42,51,52]. M1b macrophages
which predominantly develop in these conditions have been described
to being activated after endogenous danger signals, such as HMGB1,
iron, histones or ATP, ligate pattern recognition receptors [42,51–53].
Such sterile injuries can occur in many organs [54–56]. Although
inﬂammation plays an important function in limiting the numbers
of pathogens, it limits also the epithelial healing and induces tissue
damage and dysfunction. This ﬁnding was supported by showing an
improved re-epithelialization of sterile wounds in PU.1-deﬁcient mice
that lack neutrophils and macrophages, or in Myd88-deﬁcient mice
that have impaired innate immune responses [57–59]. Additionally,
reactive oxygen species or TNF-α was shown to promote cell cycle
arrest or apoptosis in epithelial and endothelial cells. A persistent
pro-inﬂammatory macrophage phenotype is sufﬁcient to turn acute
into chronic tissue inﬂammation and progressive loss of tissue [60].
Classically-activated pro-inﬂammatory macrophages amplify inﬂam-
mation and loss of parenchymal cells also in a variety of kidney diseases
such as in anti-glomerular basement membrane glomerulonephritisFig. 1. Macrophages and renal ﬁbrosis. Tissue damage activates parenchymal cells, which
monocytes that differentiate into various macrophage phenotypes depending on the local
and other innate immune receptors that drive macrophage polarization toward the ‘M1’
and other anti-inﬂammatory signals favors macrophage polarization toward anti-inﬂamm
digest ECM.[61], lupus nephritis [62–67], antigen-induced immune complex glo-
merulonephritis [68], renal allograft injury [69], ischemia reperfusion
injury [70–73], and adriamycin nephropathy [74]. Blocking the recruit-
ment and activation of M1 macrophages reduces immunopathology
in a number of inﬂammatory kidney disease models [75–77]. These
observations do not only apply to the kidney, but also to autoimmune
diseases of the central nervous system [78,79], CCl4-induced liver injury
and several other infectious and noninfectious types of inﬂammation in
solid organs [7,80]. However, some studies also document that wound
closure is signiﬁcantly delayed upon early macrophage depletion [81].
Also in sterile wounds the depletion of pro-inﬂammatory macro-
phages leads to reduced scar areas [81], but in sterile environments
the inﬂammatory phase is short-lasting. Therefore, sterile wounds
heal faster [14,82]. This is also because immunomodulatory elements
rapidly downregulate the inﬂammatory response and promote tissue
repair [83]. It is of note that certain macrophage phenotypes contribute
to this anti-inﬂammatory and pro-regeneratory phase of tissue injury
and repair.
5. Monocytic phagocytes during the resolution of inﬂammation
The sequential inﬂux of neutrophils and macrophages upon injury
is a hallmark of acute tissue damage. Macrophages are needed to
remove those neutrophils that undergo NETosis or apoptosis (Fig. 1)
[84]. The phagocytosis of apoptotic cells is a central element that
changes the phenotype of pro-inﬂammatory macrophages into anti-
inﬂammatory macrophages and subsequently promotes the resolu-
tion of inﬂammation [85,86]. This ‘waste elimination process’ avoids
persistent exposure of immunostimulatory elements to immune
cells. Furthermore, such alternatively-activated macrophages release
mediators such as IL-4, IL-13, IL-10 or transforming growth factor-β1
(TGF-β1) that rather shift tissue inﬂammation toward tissue repair
[8,9,87]. A key regulator of these processes may be circulating serum
amyloid P also known as pentraxin-2 (PTX-2), which opsonizes deadresults in subsequent activation of innate immunity. This includes the recruitment of
tissue environment. Pathogens and necrotic cells release factors that activate toll-like
proinﬂammatory macrophage. By contrast, the phagocytic uptake of apoptotic cells
atory or proﬁbrotic ‘M2’ phenotypes. Fibrolytic macrophages release proteases which
Table 1
Types of macrophage activation and their related phenotypes.
IFN-γ+PAMPs DAMPs or LPS IL-4 or IL-13 IC+LPS IL-10 or TGF-β
Stimuli (evidence from in vitro studies)
M1a
Classic type I inﬂammation
M1b
Innate inﬂammation
M2a
Alternative type II inﬂammation
M2b
Immunoregulatory
M2c
Immunosuppression
Predominant phenotypic function in inﬂammation and repair processes
Ingestion of pathogens, antigen
presentation, complement
synthesis, stimulation of
Th1 cells
Ingestion of apoptotic cells Recruitment of Th2 cells,
eosinophils and basophils,
killing of intracellular
pathogens such as
helminths
Promote Th2 responses,
IgG class switching by
B-cells, matrix synthesis
Resolution of inﬂammation,
matrix synthesis and remodeling
Inﬂammatory expression proﬁle and determinants of polarization
+ regulation: STAT1/IRF5 CD40,
CD80, CD86, MHC I and II, IL-1β,
TNF-α, IL-6, -12, -15, -18, -23,
iNOS, NO, ROS, CCL-2, -3, -5,
-8, -15, -19, -20, CXCL-9, -10,
-11, -13, MMPs
− regulation: scavenger
receptors, TIMPs IL-4, -13,
-10, TGF-β mTOR
+ regulation: STAT1/IRF5 CD40,
CD80, CD86, MHC II, IL-1β, TNF-α,
IL-6, ROS, CCL2, 3, 5, CXCL9, 10, 11,
scavenger receptor
− regulation: IL-12, IL-4, IL-13,
IL-10, TGF-β mTOR
+ regulation: STAT6/IRF4 PPARδ,
PPRγ, KLF4, IGF-1, Arg1, CD40,
CD80, CD86, MHC II, CCL2, 8, 13,
17, 26, CXCL9, 10, 11, 13, FIZZ1,
YM1, scavenger receptor, mannose
receptor, DC-SIGN, FcγR, IL-10,
IL-1RA, IL-1RII, MMP12, TGF-β,
mTOR, ﬁbronectin
− regulation: IL-1β, IL-12, NO
+ regulation: IL-10, CD40,
CD80, CD86, MHC II,
CXCL-3, CCL-1, -20, mTOR
− regulation: IL-12 secretion
of modest amount of: IL-1β,
IL-6, TNF-α
+ regulation: STAT3, scavenger
receptors A and B, IL-10, IL-1RA,
TGF-β, mannose receptor,
VEGF-C, PDGF, Arg-1, PGE2, FcγRs,
CCR-1, -2, -5, CCL-16, -18, CXCL-4,
-13, -23, SLAM, mTOR
− regulation: IL-1β, TNF-α,
IL-6, -12
Depending upon the nature of the activating stimulus activated macrophages alter their expression of cytokines, costimulatory molecules and cytotoxic apparatus to promote the
response to pathogens. M1-polarization, or classical activation, is induced by IFN-γ combined with microbial stimuli (PAMPs and DAMPs). M2-polarized macrophages have been
classiﬁed into three groups: M2a, M2b and M2c. M2a macrophages (alternatively activated macrophages), are induced by IL-4 or IL-13 treatment. M2b macrophages arise upon
stimulation with immune complexes. M2c macrophages (deactivated or regulatory macrophages), are anti-inﬂammatory macrophages generated by exposure to such stimuli
as IL-10 or TGF-β. M1-polarized macrophages cross talk with Th1 and NK cells. M2 polarization of macrophages is driven by Th2 cells, basophils and eosinophils through their
secretion of IL-4 or IL-13. M2b-like macrophages are polarized by interaction with B cells through antibody-/immune-complexes-mediated activation. M2c-like macrophages
are polarized by interaction with Treg cells. Molecular pathways of macrophage polarization include activation of the transcription factors NF-κB (p65 and p50), AP-1, IRFs and
STATs, which leads to the transcription of appropriate genes (cytokines, growth factors and surface molecules).
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alternatively-activated M2 macrophages into three subtypes: (1)
M2a activated by IL-4 or IL-13, (2) M2b activated by immune
complexes and LPS, and (3) M2c activated by IL-10 and TGF-β1
(Table 1). Generally, M2 macrophages express high levels of the
mannose receptors, of scavenger receptor A as well as FIZZ1 and
YM1. Furthermore, they produce CCL13, CCL8 or CCL26, which recruits
eosinophils, basophils, and Th2 T cells, a program which derives
from host defence against extracellular pathogens [90]. Experimental
studies showed that direct IL-4/IL-10 treatment or genetically modi-
ﬁed or transfused IL-10-stimulated macrophages help to resolve
renal inﬂammation [91–94]. IL-10, which strongly activates M2c
macrophages, was proposed to be a predominant cytokine that
orchestrates the resolution of inﬂammation. Further evidence for this
concept is provided by studies with tumor associated macrophages
(TAMs), which create a non-inﬂammatory tumor environment. TAMs
secrete large amounts of IL-10, VEGF and PDGF, which are necessary
for angiogenesis and building the tumor stroma, conceptually like a
chronic wound [95,96]. M2macrophage injection intomicewas protec-
tive in terms of inﬂammatory cytokine expression and accumulation
of pro-inﬂammatory macrophages [93]. Also steroids suppress kidney
inﬂammation by inducing anti-inﬂammatory macrophages [97]. How-
ever, depletion of anti-inﬂammatory M2 macrophage reduced muscle
regeneration [21] as well as axonal regeneration after sterile spinal
cord injury [98]. Similar positive effect of M2 macrophages on healing
processes was observed during toxic CCl4-induced liver disease [99]
and hepatic ischemia/reperfusion injury [100]. Moreover, macrophage
depletion from sterile wounds not only delays wound healing but
also leads to apoptosis of endothelial cells [81]. Thus, the switch to an
anti-inﬂammatory macrophage phenotype supports the resolution of
inﬂammation, a mandatory step for efﬁcient tissue repair.
6. Monocytic phagocytes during tissue repair and ﬁbrosis
Scarless wound healing occurs in lower animals even in non-
sterile conditions. In mammals and even human fetuses it is limited
to the sterile fetal environment or during childhood where tissuegrowth involves a higher density of tissue progenitors than in adults
[101]. The process of scarring was evolutionarily conserved and is
necessary to address the loss of tissues that cannot rapidly or only
incompletely regenerate. Insufﬁcient repair is associated with the
persistence of alternatively-activated macrophages that continue to
produce growth factors, which also stimulate ﬁbroblast activation
and ECM secretion [51]. For example, M2 macrophages secrete
large amounts of transforming growth factor-β (TGF-β), a cytokine
with anti-inﬂammatory as well as pro-ﬁbrotic functions [95]. Other
pro-ﬁbrotic factors are CTGF, CCL17, CCL22, and Igf1. TGF-β is also
up-regulated in epithelial cells that can no longer proliferate for
repair and, therefore, produce TGF-β and CTGF to activate mesenchy-
mal healing as a second line healing program [102]. In vitro, IL-4 and
IL-13 induce STAT6 signaling to promote a macrophage phenotype
that predominantly releases ECM molecules [42] and blocks inﬂam-
mation [103]. Furthermore, arginase expressed by M2 macrophages
can directly promote ﬁbrogenesis by activating the synthesis of gluta-
mate and proline which are necessary for collagen synthesis [104].
Macrophage-induced anti-inﬂammatory/pro-ﬁbrotic responses occur
inside solid organs following transient sterile inﬂammation, such as
ischemia/reperfusion [72]. In the heart, macrophages orchestrate
myocardial remodeling uponmyocardial infarction [105]. For example
after renal ischemia/reperfusion injury the phenotypic switch from
pro-inﬂammatory toward anti-inﬂammatory macrophages is driven
by tubular epithelial cell-derived factors as well as by the uptake
of apoptotic neutrophils [72,106]. Progression of glomerulosclerosis
and interstitial ﬁbrosis in murine Alport syndrome of collagen
4A3-deﬁcient mice is also associated with signiﬁcant M2 macrophage
inﬁltrates [107]. Therefore, blocking the recruitment and activation of
pro-inﬂammatory macrophages, e.g. with CCL2 antagonist, remained
ineffective in Alport syndrome as these cells do not contribute to
the progression of renal scaring [108]. The same applies to hepatic
ﬁbrosis [109,110]. In contrast, blocking CCR1, a chemokine receptor
also expressed by anti-inﬂammatory and pro-regeneratory M2 mac-
rophages, reduced macrophages, subsequent ﬁbrosis, and prolonged
survival of collagen 4A3-deﬁcient mice [111]. The pro-ﬁbrotic role
of CCR1+ interstitial macrophages was also conﬁrmed in diabetic
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renal ﬁbrosis after unilateral ureteral obstruction [112–116].
Another crucial population of immune macrophage-like immune
cells that contributes to tissue repair is circulating ﬁbrocytes [117].
Fibrocytes express the hematopoieticmarker CD45 and the progenitor
marker CD34 but they also secrete large amounts of collagen-1 [118].
Fibrocytes display a mixed phenotype between monocytic precursors
and ﬁbroblasts [119]. During inﬂammatory responses ﬁbrocytes
enter the tissue using surface CXCR4 receptor, which binds CXCL12
and participates in tissue repair [120]. Consequently, elevated
CXCL12 levels were associated with accumulation of ﬁbrocytes in pa-
tients with ﬁbrotic lung disease [121], and the presence of these cells
correlated with early mortality of patients with idiopathic pulmonary
ﬁbrosis [122]. In scleroderma patients, dermal ﬁbrocyte numbers
correlate with age and the stage of dermal ﬁbrosis [123]. They seem
to possess a unique ability to differentiate into ﬁbroblasts and into
myoﬁbroblasts upon stimulation with TGF-β [124–126]. More recently,
it has been shown that also CXCR3+ hematopoietic cells might be the
subset responsible for scar formation/ﬁbrosis [127].
Together, macrophages contribute to tissue ﬁbrosis only because
they support a mesenchymal healing response that is activated once
epithelial/parenchymal repair remains insufﬁcient. This is driven by
a microenvironment of apoptotic cells and growth factors that drive
macrophages to themselves produce pro-ﬁbrotic mediators. In chronic
disorders, especially in diffuse injuries, the process of ﬁbrosis then ac-
companies the progressive loss of function, which largely depends on
the loss of parenchyma. However, sclerosis, the functional consequence
of ﬁbrosis, can contribute to disease progression, e.g. the stiffening of
the cardiac ventricles or of the vascular wall.
7. Monocytic phagocytes during the resolution of ﬁbrosis
Distinct macrophage populations also limit or even reverse tissue
ﬁbrosis by digesting ECM deposits. Two proteolytic cascades, the
matrix metalloproteinases (MMPs) and their endogenous inhibitors
(the tissue inhibitors of metalloproteinases-TIMPs, the plasminogen
activators uPA and tPA, and the plasminogen activator inhibitors-PAIs),
regulate matrix turnover [128,129]. However, the role of MMPs in
ﬁbrosis is complex and seems to be compartment, – time – and cell
type-speciﬁc. The in vivo effects remain difﬁcult to predict because
MMPs also cleave and activate a variety of cytokines. Several studies
suggest an increase in MMP expression, rather than a loss of MMPs,
during ﬁbrosis [130,131]. For example, MMP-2, MMP-7 and MMP-9
were elevated in experimental models of lung ﬁbrosis and their
overexpression was shown to promote ﬁbrogenesis [132–134]. They
are most probably involved in basement membrane digestion, which
leads to a loss of structural integrity and contributes to parenchymal
damage and dysfunction. Furthermore, Mmp7-deﬁcient mice are
protected from bleomycin-induced ﬁbrosis [132]. However, when
macrophages are depleted in the late phase of toxic liver ﬁbrosis the
clearance of liver scars is delayed, because scar-associatedmacrophages
no longer release MMP13, which breaks down ECM [135]. Various
MMPs have been implicated in the severity of inﬂammation and ﬁbrosis
in asbestos-induced lung injury and MMP blockade attenuated inﬂam-
mation and ﬁbrosis [136]. For example, pirfenidone, an anti-ﬁbrotic
agent that decreases collagen deposition in a variety of animal models
and humans is believed tomodulateMMP activity [137]. In some exper-
imental models, pirfenidone reduced the expression of TIMP-1, MMP-2
and MMP-9 but not of MMP-13, which was associated to less TGF-β1
expression [137–139]. Macrophages also release MMP2 and MMP9
that degrade collagen in the kidney [140,141]. Interestingly, late onset
of MMP inhibition in mice with progressive renal scaring aggravated
renal ﬁbrosis, while it was protective during the early stage of the
disease [142]. It seems that certain MMPs do not only degrade collagen
but also rather digest ECM includingbasementmembranes, which com-
promises the integrity of epithelial compartments [143]. ECM breakdown also produces small ECM peptides and glycosaminoglycans,
which themselves can act as immunostimulatory DAMPs and potenti-
ate tissue inﬂammation [144]. Fibrolytic macrophages have such an ex-
cessive ﬁbrolytic activity but their phenotype has not yet been clearly
deﬁned, e.g. by their speciﬁc surface marker expression proﬁle. Recent
studies showed that treatment of cultured macrophages with M-CSF,
but not GM-CSF, shifts macrophages from antigen-presenting cells
to subpopulation of IL-10-producing suppressor cells [145]. IL-10
has immunosuppressive function, which acts on macrophages and
prevents them from production of proinﬂammatory cytokines, and to
downregulate expression of co-stimulatory molecules in a STAT3-
dependentmanner [146–148].Moreover, IL-10 produced by suppressor
macrophages prevents the development of Th1-type and Th2 T-cell
responses, and promotes the differentiation of T cells to regulatory
T-cell population [149]. Also proinﬂammatory factors such as IFN-γ
or IL-12may induce regulatorymacrophage population. Various studies
demonstrated that continuous exposure of macrophages to TLR2, TLR4
or TLR9 ligands leads to development of immunosuppressive state
[150–152].
Latest studies identiﬁed also non-proteolytic and antiﬁbrotic
factors such as BMP7. BMP7 is one of over 20 known members of
BMP family that are structurally and functionally related and are
part of TGF superfamily of cytokines [153]. BMP7 is indispensable for
normal kidney development [154]. However, unlike TGF-β, BMP7
was found to be downregulated in experimental and human ﬁbrosis
[28,155]. Furthermore, the kidney mesenchymal cells of BMP7 null
embryos were not able to differentiate [156]. Other studies have
demonstrated that BMP7 protects the kidney from injury by enhancing
the survival ability of tubular cells and reduction of inﬂammation
[157,158]. Therefore, BMP7 might be a crucial survival and differentia-
tion factor for kidney mesenchymal cells.
Taken together, macrophages already contribute to the break-
down and turnover of ECM during homeostasis but this property
becomes more prominent in the microenvironment of scar tissue.
Removing ﬁbrous tissue is the ﬁnal phase of the wound healing
process. Activating the ﬁbrolytic properties of these macrophages
may be another option to reverse tissue ﬁbrosis. Such ﬁbrolytic mac-
rophage populations have been described in some organs but deserve
further phenotypic characterization.
8. Summary
Tissue mononuclear phagocytes can display a phenotype of
resident dendritic cells or of resident macrophages, but they are im-
portant for maintaining homeostasis. During tissue injury changing
tissue environments shape the phenotype of these mononuclear
phagocytes to provide them with additional functional properties
that meet the tissues' need to address the danger. It is instrumental
to apply the model of (dermal) wound healing upon traumatic injury
to better understand their role in each of the phases of danger control
and tissue repair also in other organs. Accordingly, pro-inﬂammatory
(M1) macrophages support host defense by enhancing the inﬂamma-
tory environment even in sterile tissue injuries. The inﬂammatory re-
sponse following tissue injury has important roles in both normal and
pathological healing. Immediately after injury, the innate immune
system is activated and is responsible for recruitment of inﬂammato-
ry cells from the circulation. Local, resident immune cells, including
macrophages produce chemoattractans that enhance inﬂammatory
responses by recruiting more leukocytes. Understanding of macro-
phage population switch and mechanisms which regulate macro-
phage function seems to be an attractive therapeutic target, both
to reduce ﬁbrosis and scarring, and to improve healing of chronic
wounds. It seems that during normal inﬂammation, which includes
mast cell degranulation and neutrophil inﬁltration, macrophages
have an important balancing role. Thus, the role of macrophages
must always be considered in the context of the speciﬁc environment.
994 M. Lech, H.-J. Anders / Biochimica et Biophysica Acta 1832 (2013) 989–997Anti-inﬂammatory macrophages support the resolution of inﬂam-
mation. This process involves the expression of growth factors that
promote parenchymal repair, which includes mesenchymal repair.
For example, the anti-inﬂammatory cytokine TGF-β1 is a potent
pro-ﬁbrotic cytokine that activates mesenchymal repair mechanisms.
Finally, macrophages contribute to the removal of ﬁbrous tissue.
Mediating the resolution phase of healing includes capillary regres-
sion and collagen remodeling. Macrophages can produce factors
that terminate the repair response. However, little is known about
how a particular population of macrophages terminates the healing
response but the agent modulating the phenotype of these particular
macrophages or ex-vivo production of such cells possesses great
therapeutic potential. Furthermore, using single macrophage factors
as therapeutics raise difﬁculties with optimumdelivery systems, timing
and concentration, not to mention the proteolytic condition which
limits the half-life of therapeutic agents. One alternative would be in
situ activation, recruitment or addition of exogenous macrophages
which are source of beneﬁcial growth factors and cytokines that stimu-
late regeneration of damaged tissue, angiogenesis and actively leads
to resolution of established ﬁbrosis. However, increasing the number
of macrophages in the ﬁbrotic tissue might imbalance the environment
and macrophages might switch again the phenotype and potentiate
inappropriate conditions such as inﬂammation instead of resolution
of ﬁbrotic tissue or regeneration. The strategy of driving macrophages
within tissue toward a suppressor phenotype might be a promising
therapeutic approach opening a novel area of cell-based medicinal
products.
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